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CASE REPORT
Obsessive-compulsive disorder followed by psychotic episode in long-
term ecstasy misuse
CARLO MARCHESI, MATTEO TONNA & CARLO MAGGINI
Department of Neuroscience, Psychiatric Division, University of Parma, Italy
Abstract
Aim. We report the case of two young subjects who developed an obsessive-compulsive disorder (OCD) during a heavy use
of ecstasy. After several months of discontinuation of the drug, major depression with psychotic features developed in one
subject and a psychotic disorder in the other individual. No mental disorder preceded the use of ecstasy in any subject.
Findings. A familial and personality vulnerability for mental disorder was revealed in one subject, but not in the other, and
all physical, laboratory and cerebral NMR evaluations showed normal results in both patients. Remission of OCD and
depressive episode or psychotic disorder was achieved after treatment with a serotoninergic medication associated with an
antipsychotic. Conclusions. The heavy long-term use of ecstasy may induce an alteration in the brain balance between
serotonin and dopamine, which might constitute a pathophysiological mechanism underlying the onset of obsessive-
compulsive, depressive and psychotic symptoms. The heavy use of ecstasy probably interacted with a vulnerability to
psychiatric disorder in one subject, whereas we cannot exclude that an ‘‘ecstasy disorder’’ ex novo affected the other
individual.
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Introduction
The use of ecstasy (MDMA) can induce acute
psychological effects including: (1) generally, eu-
phoria and reduction of negative thoughts; (2)
sometimes, hyperactivity, flight of ideas, insomnia,
hallucinations, depersonalisation, anxiety, agitation
and bizarre behaviour; (3) occasionally, panic at-
tacks, delirium, or brief psychotic episodes (Green
2003).
In addition, MDMA shows long-term effects,
which outlast the actual drug experience by months
or years, such as cognitive impairment, greater
impulsivity, panic attacks, recurrent paranoia, hallu-
cinations and severe depression (Kalant 2001; Green
2003).
An increase in serotonin (5-HT) and dopamine
(DA) release is the major mechanism underlying the
acute mental effects of ecstasy (Kalant 2001),
whereas the long-term effects have been suggested
to depend on a decrease of serotoninergic function.
This damage has been clearly demonstrated
in animal experiments (Green 2003; Gouzoulis-
Mayfrank and Daumann 2006). In humans, one
postmortem study (Kish et al. 2000) reported severe
depletion (5080%) of striatal 5-HT and 5-HIAA in
the brain of a 26-year-old male subject who had
regularly taken MDMA for 9 years. Moreover,
several studies found a reduction of 5-HIAA in the
cerebrospinal fluid of ectasy users, and brain ima-
ging studies suggested a brain damage and glial
proliferation in heavy MDMA users (Gouzoulis-
Mayfrank and Daumann 2006). Therefore, some
evidence suggests that a long-term effect of MDMA
might induce brain alterations, particularly involving
the serotoninergic system. However, some metho-
dological problems suggest caution to infer a causal
relationship between MDMA use, cerebral altera-
tions and the onset of psychopathological conditions
(Curran 2000).
We present the clinical history of two patients who
showed the onset of obsessive-compulsive disorder
(OCD) after a long period of use of ecstasy alone.
Moreover, many months after discontinuation of
MDMA, a depressive episode with psychotic fea-
tures developed in one patient and a psychotic
disorder in the other.
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Case one
A 16-year-old girl used ecstasy for 1 year (four to five
tablets per week; total lifetime intake of about 200
tablets). After the first 23 months of MDMA
consumption, the patient began to spend most of
her time performing complex rituals before leaving
or after returning home. The compulsive behaviour
was associated with obsessive thoughts: obsessive
phobias, numerical, symmetry and order obsessions,
over-crowding of thoughts accompanied by poor
insight and resistance. The disorder significantly
interfered with her daily life: even automatic
activity such as writing or walking became influ-
enced by exact, compulsive rules. The great inter-
ference of compulsive behaviour led the patient to
abandon the school. She discontinued MDMA use
because she considered ecstasy responsible for the
OCD. After discontinuation, the OCD improved but
did not disappear. Three months later, the patient
was hospitalised for the onset of a severe depressive
episode with psychotic features and worsening of
the OCD. Anamnestic information did not report
the existence of mental disorders before the ecstasy
use. Moreover, clinical evaluation showed the pre-
sence of major depression and delusional disorder in
relatives. Finally, the patient was diagnosed, using
the Structured Interview for DSM-IV personality
disorders (Pfohl et al. 1997), as affected by a
borderline personality disorder. All physical, labora-
tory and cerebral NMR evaluations failed to show
abnormal results. After 2 months of treatment with
an antidepressant (clomipramine) and an antipsy-
chotic (olanzapine), remission of depressive episode
and OCD was achieved.
Case two
A 23-year-old man started to use MDMA at
20 years of age and stopped the drug use after
more than 2 years of consumption (one to two
tablets per week for a total lifetime intake of about
150 tablets) because of the sudden onset of obses-
sions of contamination. The obsessions were asso-
ciated with a compulsive potomanic behaviour,
justified by the patients the need for ‘‘inner’’
purification. The severity of symptoms induced a
water intoxication and the patient was hospitalised in
a medical ward. After discharge, the obsessions of
contamination worsened and were associated with
different and complex compulsive acts of purifica-
tion which caused great interference in his daily life;
particularly, he was unable to work and to attend his
daily activities. Eight months after MDMA discon-
tinuation, a psychotic disorder developed and the
patient was hospitalized in a psychiatric clinic. All
physical, laboratory and cerebral NMR evaluations
failed to show abnormal results. Anamnestic infor-
mation and clinical evaluations did not support the
existence of a mental or a personality disorder before
the use of ecstasy. Moreover, no mental disorder was
found in any relative. He was treated with an
antipsychotic (risperidone) and a serotoninergic
antidepressant (sertraline). A complete remission
of both psychotic and obsessive-compulsive symp-
toms was achieved only after 1 year of treatment.
Discussion
These case reports raise the question about the
causal relationship between ecstasy misuse and onset
of mental disorders. It is not easy to answer the
question of whether MDMA induced psychopatho-
logical conditions in these subjects. However, we
must take into account several findings.
No mental disorder affected the two patients
before the use of ecstasy. Therefore, we can exclude
that they used ecstasy as a self-medication for a pre-
existing depressive or anxiety disorder, as suggested
by previous studies (Curran 2000; Lieb et al. 2002;
Huizinik et al. 2006).
During the abuse of ecstasy, the two patients did
not use any other drugs. Almost only poly-drug
abusers were evaluated in previous studies investi-
gating psychopathological effects of ecstasy. Con-
comitant opiate and alcohol addiction was found to
be a risk factor for developing mental disorders in
ecstasy users (Schifano et al. 2000).
The two patients first developed OCD after long-
term use of ecstasy. In agreement with this finding,
in a previous study Parrott et al. (2001) observed
higher scores in OC subscale of SCL-90 in heavy
ecstasy poly-drug users than in control subjects;
more recently (Lieb et al. 2002), the prevalence of
OCD was found to be twice as frequent in MDMA
users than in non-users. However, the onset of OCD
followed the drug abuse in only a minority (16%) of
ecstasy users.
A dysfunction of the serotoninergic system has
been hypothesized to underline the development of
OCD in non-addicted subjects (Aouizerate et al.
2004; Chamberlain et al. 2005). In fact, the specific
treatment response to serotoninergic medications
and the transient exacerbation of symptoms after a
pharmacological challenge with specific 5HT ago-
nists suggest that an imbalance of 5HT is involved in
the pathogenesis of OCD (Zohar et al. 2000;
Micallef and Blin 2001).
A psychotic depressive episode or a psychotic
disorder developed in the patients some months
after MDMA discontinuation. Previous studies re-
ported a high prevalence (nearly 30%) of depression
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in MDMA users (Schifano et al. 1998; Topp et al.
1999; Lieb et al. 2002). Interestingly, in a high
percentage (40%) of the ecstasy users major depres-
sion developed after drug abuse (Lieb et al. 2002).
Also psychosis is a well-documented psychopatho-
logical condition associated with MDMA use
(McGuire et al. 1994; Schifano et al. 1998; Topp
et al. 1999; Curran et al. 2004). However, psychosis
induced by ecstasy use is generally a short-lasting
disorder (Topp et al. 1999; Curran et al. 2004),
whereas in our patient the psychotic symptoms
remitted after 1 year of treatment.
The association between OCD and major depres-
sion or psychotic disorder is a well-documented
clinical condition in non-addicted patients (Aouize-
rate et al. 2004; Chamberlain et al. 2005). Recently,
this association has been investigated in neurophy-
siological, neuropsychological and neuroimaging
studies (Aouizerate et al. 2004; Poyurovsky et al.
2004; Chamberlain et al. 2005; Bottas et al. 2005).
The 5HT/DA dysfunction in cortical-striatal-thala-
mic-cortical pathways has been suggested as a
possible pathophysiological mechanism underlying
the association between obsessive-compulsive, de-
pressive and psychotic symptoms in non-addicted
patients.
Acutely, MDMA is known to increase 5HT and
DA activity, whereas long-term use decreases 5HT
function (this effect was observed after using ecstasy
25 times) (McCann et al. 1998). The long-term
effect on the DA system appears to be more
controversial (Green et al. 2003; Gon˜i-Allo et al.
2006). Therefore, the MDMA effect on the seroto-
ninergic and probably on the dopaminergic system
might be involved in the onset of psychopathological
conditions, such as major depression, anxiety and
psychotic disorders, in ecstasy users. In accord with
this hypothesis, a higher incidence of these disorders
was found in subjects with pre-existing MDMA
misuse (Lieb et al. 2002), particularly in heavy users
(Schifano et al. 1998).
Mental disorders do not develop in all ecstasy
users. Therefore, a pre-disposition to psychiatric
illnesses may need to exist for psychopathological
symptoms to develop in some ecstasy users.
In view of these observations, a specific causal role
as a primary risk factor for the onset of mental
disorders in our patients cannot be attributed to
ecstasy with certainty, even though heavy use of the
drug lasted several months and was followed by
mental disorders. However, in one of our patients
ecstasy misuse probably interacted with a vulner-
ability to psychiatric disorders. In fact, the girl was
affected by a borderline personality disorder which
predisposes people to suffer from several mental
disorders, such as substance abuse, depression,
anxiety and eating disorders (Skodol et al. 2002;
Lieb et al. 2004). Moreover, this patient also showed
a familial vulnerability to major depression and
psychotic disorder (Shih et al. 2004). In contrast,
the young man did not show any personality or
familial predisposition to mental disorders. How-
ever, we cannot exclude that this patient might have
been vulnerable to psychotic disorders, because his
psychotic disorder lasted much longer than the usual
ecstasy-induced psychosis (Curran et al. 2004).
Therefore, the onset of the mental disorder in the
girl was probably induced by the interaction between
ecstasy misuse and personality and familial vulner-
ability rather than representing an ex novo ‘‘ecstasy
disorder’’. In contrast, it is difficult to say whether an
ex novo ‘‘ecstasy disorder’’ affected the young man.
Conclusion
Our case reports suggest that the assessment of
personality and psychiatric family history in ecstasy
users might be a useful clinical tool: (1) to identify a
predisposition for the development of mental dis-
orders; (2) to verify the association between ecstasy
abuse and the onset of a specific mental disorder in
vulnerable individuals; and (3) to clarify whether
ecstasy may induce mental disorders in absence of
other risk factors.
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